EMA draft agenda lists ENFLONSIA application among items scheduled for adoption, without confirming opinion
Key Facts
A positive opinion from the Committee for Medicinal Products for Human Use on expanding the use of ENFLONSIA could not be confirmed on the day of the story, according to an available European agenda. The draft shows the application listed among items scheduled for adoption, but does not establish that the committee issued a final opinion. The application concerned children under age two at increased risk of severe respiratory syncytial virus disease during their second season. In an earlier statement, Merck said the European agency accepted the extension application in July 2026. Acceptance of an application is a procedural step before assessment and does not mean the extension has been approved.
Merck said the European extension application, along with the U.S. application, is based on data from the Phase 3 SMART study. The application concerns a group of children who, according to the company, remain at risk of severe disease in their second season despite receiving protection in the first season. The requested assessment therefore focuses on whether use can be extended to a later season of virus exposure for children at higher risk. The company submitted the study results as scientific support for the application, not as a decision issued by a regulatory authority. Any European extension of use remains subject to completion of the regulatory process and a decision by the competent authority.
In SMART results announced by the company, the rate of respiratory syncytial virus-associated lower respiratory tract infections with at least one clinical indicator or severity warranting attention was 7.3% among children who received ENFLONSIA in their second season. The rate of virus-associated hospitalization was 3.0% in the same group. The results covered a follow-up period through day 180, or six months. Merck attributed these rates to elevated underlying risks and the burden of disease after the pandemic. The company used the results to support its application for children under age two at increased risk, but they do not in themselves constitute a final regulatory judgment.
Merck added that antibody concentrations in at-risk children in their second season were similar to those in healthy infants in the CLEVER study. It said the SMART results support extrapolating efficacy to children under age two at risk of severe disease in their second season. This extrapolation forms part of the scientific argument the company submitted to regulators. First-season data in higher-risk infants showed rates of respiratory syncytial virus-associated lower respiratory tract infections requiring medical attention of 3.2% with ENFLONSIA and 3.4% with palivizumab through day 150, or five months. The company statement described the rates as broadly similar, in a comparison concerning the first season rather than the European application to extend use into the second season.
Merck shares, trading under the ticker MRK, closed at 146.95 dollars on November 12, 2026, according to EL7 data. No documented details on the session's high or low share price were available in the information provided. The article also contains no documented figure for the market reaction to the European regulatory process. The share close was from the session before the story date, but does not establish that investors priced in the possibility of a European opinion. The price therefore remains a figure for that session, separate from a regulatory outcome whose issuance was not confirmed.
In the United States, the Food and Drug Administration set March 22, 2027, as its target date for a decision on the extension application, according to a Merck statement. That date applies to the U.S. application and does not represent a timeline for a decision on the European application. The company's statement said the European agency accepted the application in July 2026, while the EMA draft agenda listed the item among those scheduled for adoption. The European process thus remains separate from the announced U.S. date. Any subsequent European decision concerns assessment of an application to extend use to at-risk children during their second season.